Bortezomib

Generic Name: Bortezomib

Brand Names: Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₅BN_₄O_₄

CAS Number: 179324-69-7

Unique Ingredient Identifier: 69G8BD63PP

Background: Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication: Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions: Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

Bortezomib in Intrahepatic Cholangiocellular Carcinoma

Phase 3

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Bortezomib

First Posted Date: 2017-11-17

Last Posted Date: 2017-11-17

Lead Sponsor: Zhengang Yuan

Target Recruit Count: 50

Registration Number: NCT03345303

Locations: 🇨🇳
Easter hepatobiliary surgery hospital, Shanghai, Shanghai, China

Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.

Completed

Conditions: Chemotherapy Induced Peripheral Neuropathy
Multiple Myeloma

First Posted Date: 2017-11-17

Last Posted Date: 2020-11-12

Lead Sponsor: University Hospital, Clermont-Ferrand

Target Recruit Count: 67

Registration Number: NCT03344328

Locations: 🇫🇷
CHU Clermont-Ferrand, Clermont-Ferrand, France

Study of VTD in Waldenstrom's Macroglobulinemia

Phase 2

Conditions: Lymphoplasmacytic Lymphoma
Waldenstrom Macroglobulinemia

Interventions: Drug: Bortezomib

First Posted Date: 2017-11-07

Last Posted Date: 2017-11-07

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 15

Registration Number: NCT03335098

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 3

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Isatuximab SAR650984
Drug: Bortezomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2017-10-24

Last Posted Date: 2024-11-27

Lead Sponsor: Sanofi

Target Recruit Count: 475

Registration Number: NCT03319667

Locations: 🇺🇸
Investigational Site Number: 8400006, Fort Myers, Florida, United States
🇺🇸
Investigational Site Number: 8400004, Saint Petersburg, Florida, United States
🇺🇸
Investigational Site Number: 8400007, Kansas City, Missouri, United States

and more 101 locations

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Daratumumab
Drug: Venetoclax
Drug: Bortezomib

First Posted Date: 2017-10-19

Last Posted Date: 2024-06-17

Lead Sponsor: AbbVie

Target Recruit Count: 156

Registration Number: NCT03314181

Locations: 🇦🇺
Eastern Health /ID# 165850, Box Hill, Victoria, Australia
🇨🇦
Cross Cancer Institute /ID# 203114, Edmonton, Alberta, Canada
🇯🇵
Kameda General Hospital /ID# 225246, Kamogawa-shi, Chiba, Japan

and more 37 locations

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Phase 3

Active, not recruiting

Conditions: Amyloidosis

Interventions: Drug: Daratumumab
Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Dexamethasone, 40 mg

First Posted Date: 2017-06-28

Last Posted Date: 2024-10-26

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 416

Registration Number: NCT03201965

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 137 locations

MUK Nine b: OPTIMUM Treatment Protocol

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Lenalidomide
Drug: Daratumumab
Drug: Dexamethasone
Drug: Melphalan
Drug: Filgrastim

First Posted Date: 2017-06-15

Last Posted Date: 2024-05-14

Lead Sponsor: University of Leeds

Target Recruit Count: 95

Registration Number: NCT03188172

Locations: 🇬🇧
Bristol Haematology & Oncology Centre, Bristol, United Kingdom
🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧
Birmingham Heartlands Hospital, Birmingham, United Kingdom

and more 18 locations